InsiderPulseNo transactions found.
No annual data found.
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
Emerging Hope in Multiple Myeloma Market: 7 Late-Stage Therapies Nearing the Finish Line | DelveInsight
Myasthenia Gravis Market Set to Surpass USD 16 Billion by 2036, Fueled by Rising Diagnosed Prevalence and Wave of Targeted Biologic Approvals | DelveInsight
We're Keeping An Eye On Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn Rate